In this consult series, experts from SMFM discuss the evaluation and management of soft ultrasound markers for aneuploidy.
What every OB/GYN needs to know to manage this complication.
A recent study analyzing patient portal use amidst the COVID-19 pandemic unveils changes in sociodemographic trends and disparities, highlighting shifts in user behavior and access challenges.
The FDA has granted a regular approval to dostarlimab-gxly (Jemperli; GSK) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
In this consult series, experts from SMFM discuss the evaluation and management of soft ultrasound markers for aneuploidy.
Combined hormonal contraceptives such as the combined oral contraceptive pill, the patch, and the vaginal ring each have unique considerations for use in patients with obesity.
First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.
Emerging technology helps ensure best practices while reducing costs of care.
Family history assessment, genetic screening are key to prevention.
Risk assessment, lifestyle counseling, adverse effects, and medication management.
A teenager’s day-to-day behavior can vary greatly. Here are some tips for understanding and navigating this challenging time.
Clinical pearls for assessment and management of the pregnant patient with a uterovaginal anomaly.
Review bladder disorders and management methods you can discuss with your patients.
Today is Physician Family Day, the perfect time to reflect and address any potential burnout symptoms and spend quality time re-engaging with your loved ones.
Risk assessment and management of brain arteriovenous malformations in pregnancy.
New trial results showed statistically significant improvements in overall survival and progression-free survival.
Cancer programs seek to remove barriers to screenings.
Kate White, MD, MPH, and Harold Bays, MD, discuss their hopes for the future of contraception options, affordability, and clinical trials evaluating their efficacy.
Abbott's Lingo and Libre Rio CGM devices, designed for general health and Type 2 diabetes management respectively, receive FDA approval, offering advanced metabolic health tracking for US consumers.
Postpartum psychosis is experienced by 1 to 2 women every 1000 deliveries.
Understanding the technology behind a newer uterus-sparing option for the management of uterine fibroids.
Data has indicated an increased prevalence of atopic dermatitis among female patients compared to male patients.
Experts discuss management of women’s health including chronic pelvic pain resulting from endometriosis and heavy menstrual bleeding from uterine fibroids. They also discuss ways to help improve patient-provider communications and overcome the normalization associated with non-malignant gynecological conditions.
Oral contraceptive pills are a popular choice for many; providers should understand the options to guide patients effectively.
In this month's Practice Matters column, James D. Keller, MD, MHSA; and Brian K. Iriye, MD, explore the world of value-based care and how it can benefit your practice.
Treatment programs that often use neoadjuvant chemotherapy as a strategy may help prolong survival in patients with advanced ovarian cancer compared with those that infrequently used the tactic, which may reassure patients and providers.
Three esteemed surgeons discuss technology, weighing the pros and cons of existing and newly developed platforms.
Experts discuss the trajectory of CMV awareness and vaccine development efforts.
Here’s why we should be paying special attention to women’s depression treatment.
Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.